TCT-143
Abstract Withdrawn

TCT-144
Impact of chronic kidney disease on platelet reactivity and clinical outcomes of patients undergoing percutaneous coronary intervention
Fabio Mangiacapra1, Elisabetta Riccio1, Emanuele Barbato2, Giuseppe Patti3, Vincenzo Vici1, Andrea D’Ambrosio1, Bernard De Braye2, William Wijns1, Germano Di Sciascio1
1Catholic University of Rome, Rome, Italy

Background: Platelet reactivity is a well-established determinant of clinical outcomes after percutaneous coronary intervention (PCI). Conflicting data have been reported concerning the impact of chronic kidney disease (CKD) on residual platelet reactivity (RPR) post PCI. However, when a high proportion of patients undergoing PCI have a history of (recently re-)defined CKD, the impact of this condition on PCI outcomes may be underestimated. The aim of the present study was to compare PR and its association with clinical outcomes after PCI in CAD patients with and without CKD.

Methods: In 800 patients treated with clopidogrel we measured PR using the VerifyNow P2Y12 assay immediately before PCI (residual given as P2Y12 reaction units [PRU]). According to previous studies, we defined HPR as a PRU value ≥240 and LPR as a PRU value ≤178. CKD was defined as a glomerular filtration rate <60 mL/min/1.73 m². Clinical follow-up at 30 days was obtained in all patients. Net adverse clinical events (NACE) were considered as ischemic death, myocardial infarction and target vessel revascularization and bleeding events (according to TIMI criteria).

Results: Patients with (n=173, 21.6%) and without CKD showed similar PRU values (208.6±7 vs. 207.7±5, p=0.819). The incidence of 30-day ischemic death (12.1% vs. 7.2%; p=0.036) and bleeding events (8.7% vs. 2.1%; p<0.001) was higher in the CKD group. The incidence of death was associated with higher rates of ischemic events in both patients with (21.1% vs. 7.6%; p=0.012) and without CKD (12.6% vs. 4.7%; p<0.001). Likewise, LPR was associated with higher rates of bleeding in both patients with (19.3% vs. 3.4%; p<0.001) and without CKD (5.1% vs. 0.5%; p<0.001). NACE were significantly higher in CKD patients with HPR or LPR (25.8%) and lowest in those without CKD, HPR or LPR (6.6%; p for trend ≤0.001). At multivariate analysis, the combination of CKD with LPR or HPR was the strongest predictor of NACE (odds ratio 3.4, 95% confidence interval 2.0-5.6; p<0.001).

Conclusions: We did not find an association between CKD and higher levels of residual PR on clopidogrel. However, the combination of CKD with either high or low platelet reactivity is a strong determinant of adverse events after PCI.

TCT-145
The significance of VARC-defined acute kidney injury after transcatheater aortic valve implantation using the balloon-expandable Edwards bioprosthesis
Muhammad Khawaja1, Martyn Thomas2, Abhishek Arrey3, Karen Wilson1, Kirsty Bolter2, Jane Hancock2, Christopher Young2, Vinayak Bapati2, Simon Redwood2
1King’s College London, London, United Kingdom, 2St Thomas’ Hospital, London, United Kingdom, 3St Thomas’ Hospital, LONDON, United Kingdom, 4King’s College London, LONDON, United Kingdom, 5St Thomas’ Hospital, LONDON, United Kingdom, 6King’s College London/ St Thomas’ Hospital, London, United Kingdom

Background: Acute kidney injury (AKI) is a potentially serious complication of transcatheter aortic valve implantation (TAVI) that has recently been re-defined by the Valve Academic Research Consortium (VARC). The aim of this study was to identify the incidence and risk factors for AKI after TAVI.

Methods: We performed a retrospective analysis of data from 248 consecutive patients undergoing TAVI using the Edwards bioprosthesis at St Thomas’ Hospital, London, UK. AKI was defined as a VARC-modified Risk, Injury, Failure, Loss, and End-stage Renal disease (RIFLE) kidney disease score ≥2.

Results: Of 248 patients who underwent TAVI using the Edwards bioprosthesis 89 (35.9%) of patients suffered an acute kidney injury as defined by the score of ≥2 on the VARC-modified RIFLE score. The overall mean pre-procedural creatinine was 116.6±69.3 μmol/L with an overall peak creatinine of 148.8±94.4 μmol/L (p<0.001). Patients with AKI had greater mean pre-procedural (134.7±74.5 vs. 106.5±64.2 μmol/L; p<0.001), 48h (206.8±98.1 vs. 98.0±40.0 μmol/L; p<0.001)) and 72h creatinine concentrations (205.9±88.3 vs. 99.3±39.6 μmol/L; p<0.001). A higher VARC-modified RIFLE score was associated with increased mortality (p<0.001). Kaplan Meier analysis according to incidence of RIFLE score ≥2 (i.e. AKI) demonstrated increased mortality at 30 days (13.5% vs. 3.8%), 1 year (31.5% vs. 15.0%) and overall (40.4% vs. 19.5%; logrank p<0.001) at a median follow up of 379 days (interquartile range 113-729 days). Multivariable logistic regression analysis revealed that the variable with the strongest independent association with risk of AKI was DM (OR 3.17, 95%CI 1.67-6.05, p<0.001), followed by peripheral vascular disease (OR 2.54, 95%CI 1.34-6.44, p=0.007) and the pre-procedural stage of chronic kidney disease (OR 1.57, 95%CI 1.13-2.21, p<0.001).

Conclusions: Greater than 1/3 of patients sustain AKI after TAVI using the Edwards bioprosthesis, as defined by the VARC-modified RIFLE score. AKI was associated with increased mortality at both 30-days and at 1-year. A history of diabetes mellitus, peripheral vascular disease and higher chronic kidney disease stage had the strongest independent associations with post-TAVI AKI.

TCT-146
The Effect of Drug-Eluting Stents on Clinical and Angiographic Outcomes in Renal Failure Patients with Dialysis: Multicenter Registry in Asia
Sanao Nakamura1, Hisao Ogawa2, Jang-Ho Bae3, Yeo Cahyadi4, Wasan Udachalerm5, Damras Trexus6, Sudaratana Tanongwathanakul7
1New Tokyo Hospital, Chiba, Japan, 2Kumamoto University Hospital, Kumamoto, Japan, 3Konyang University Hospital, Daejeon, Korea, Republic of, 4Husada Hospital, Jakarta, Indonesia, 5King Chulalongkorn Memorial Hospital, Bangkok, Thailand, 6Faculty of Medicine Siriraj Hospital, Bangkok, Thailand, 7Chest Disease Institute, Nonthaburi, Thailand

Background: Patients treated with renal failure have been reported having high incidence of mortality and other complications rate after PCI. Optimal treatment of PCI for renal failure patients with dialysis is still unknown. Aim: The aim of this study is to compare the safety and efficacy of Sirolimus (SES), Paclitaxel (PES), EPC capture (ECS), Zotarolimus (ZES-R/ Endeavor Resolute), BiolimusA9 (BES) and Everolimus-eluting stent (EES) on the outcome of percutaneous coronary intervention in renal failure patients with dialysis (CRF-HD).

Methods: A prospective analysis of 1013 patients with CRF-HD (258 SES, 244 PES, 77 ECS, 118 ZES-R, 128 BES, 188 EES) in six high volume Asian centers after successful stenting was performed. The study endpoints were 30 days major adverse cardiac events (MACE) and 12, 24 and 36 months target lesion revascularization (TLR) and MACE.

Results: The baseline clinical characteristics between 5 groups were similar. See table for clinical results.

Conclusions: The use of drug-eluting stents in patient with CRF-HD was safe with low acute complication. Patients treated with PES and EES showed lesser incidence of restenosis rate and TLR compared with other drug-eluting stents.

TCT-147
High dose Atorvastatin Pretreatment for Preventing Contrast-Induced Nephropathy in Patients Receiving Primary Percutaneous Coronary Intervention: Prespecified Substudy of a Prospective Randomized Clinical trial
Sang-Ho Jo1, Hyun-Sook Kim2, Jin-Ho Choi3, Seung-Hyuk Choi4, Joo-Yong Hahn5, Sung Yun Lee6, Young Bin Song5
1Hallym University Sacred Heart Hospital, Anyang-st, Gyeonggi-do, Korea, Republic of; 2Hallym University Sacred Heart Hospital, Anyang, Anyang, Anyang-do, Korea, Republic of; 3Hallym University Sacred Heart Hospital, Anyang, Kyonggi-do, Korea, Republic of; 4Samsung Medical Center, Seoul, Korea, Republic of; 5Hun Park Hospital, Goyang, Korea, Republic of

Background: Controversies persist whether statin pre-treatment can prevent contrast-induced nephropathy(CIN). We evaluate the efficacy of high dose atorvastatin on CIN occurrence.

Methods: We studied whether atorvastatin 80mg loading and subsequent use for 5days (high dose group[HD]) could prevent CIN as compared to those received atorvastatin 10mg (routine dose group[RD]) with same schedule in patients with ST-elevation myocardial infarction undergoing primary angioplasty. Primary endpoint was incidence of CIN, defined as ≥25% or ≥0.5 mg/dl increase in baseline serum creatinine within 5 days after contrast administration. Secondary endpoint was 1- and 6-month renal function change and composite of all cause mortality, renal failure, heart failure and target vessel revascularization.

Results: One hundred and ten patients were allocated to HD and 108 to RD from August 2007 to February 2009. CIN incidence was 5.5% (6/110) in HD and 10.2% (11/108) in RD, a nonsignificant difference (p=0.149). CIN occurred significantly less in HD than RD, 0% vs. 16.7% (p=0.025) in subgroups of renal insufficiency (creatinine clearance (CrCl)≤60ml/min) and 4% (1/25) and 23.1% (6/26) respectively, (p=0.048) in old patients≥70. Composite of clinical outcomes at 6-month was comparable in HD and RD (7.9% and 13.1%, p=0.26). CrCl≥17 ml/min to be higher, in HD than in RD, 81
Trial Impact of Chronic Kidney Disease on Myocardial Infarct Size and Adverse TCT-149 mortality. These findings indicate that outcome of TAVI may be improved by more

Conclusions: High dose atervastatin treatment does not prevent CIN in patients receiving primary angioplasty. However it demonstrated potential of lowering CIN in patients with renal insufficiency and elderly.

1Thoraxcenter, Erasmus Medical Center, Rotterdam, Rotterdam, Zuid Holland, 2Québec Heart and Lung Institute, Quebec, Canada, 3University Hospital Bonn, Bonn, Germany, 4University Hospital Maastricht, Maastricht, Netherlands, 5University Hospital Saint-Luc, Brussels, 6University Hospital Antwerp, Antwerp, Belgium, 7Angiography de Occidente, SA, Cali, colombia, 8Erasmus MC, Rotterdam, Netherlands, 9Quebec Lung and Heart Institute, Laval University, Quebec, Quebec, 10University Hospital Bonn, Bonn, NRW, 11University Hospital Maastricht, Maastricht, 12Angiography de Occidente SA, Cali, Cali, 13Québec Heart and Lung Institute, Laval University, Quebec, QC, 14Thoraxcenter, Erasmus MC, Rotterdam, Netherlands, 15Thoracenter, Erasmus Medical Center, Rotterdam, Rotterdam, Netherlands

Background: Blood transfusion is associated with acute kidney injury (AKI) after transcatheter aortic valve implantation (TAVI). We sought to elucidate in more detail the relation between blood transfusion and AKI and its effects on short- and long-term mortality.

Methods: 995 patients with aortic stenosis underwent TAVI with the Medtronic-CoreValve or the Edwards Valve in 7 centers. AKI was defined by the Valve Academic Research Consortium (absolute increase in serum creatinine ≥0.3 mg/dl (≥26.4 μmol/l) or ≥50% increase ≥72 hr). Logistic and Cox regression was used for predictor and survival analysis.

Results: AKI occurred in 20.7% (n = 206). The number of units of blood transfusion ≤24 hr was the strongest predictor of AKI (≥5 units: OR: 4.81 [1.45-15.95], 3-4 units: OR: 3.05 [1.24-7.53], 1-2 units: OR: 1.47 [0.98-2.21]) followed by peripheral vascular disease (OR: 1.48 [1.05-2.10]), history of heart failure (OR: 1.43 [1.01-2.03]), leucocyte count (OR: 2.05 [1.24-7.53], 1-2 units, OR: 1.47 [0.98-2.22]) followed by peripheral vascular disease (OR: 1.48 [1.05-2.10]), history of heart failure (OR: 1.43 [1.01-2.03]), leucocyte count (OR: 3.04 [1.52-6.07], OR: 5.39 [2.14-13.57], respectively) while transfusion of 3-4 units of blood transfusions in comparison to patients without anemia before TAVI (OR: 1.48 [1.05-2.10]), history of heart failure (OR: 1.43 [1.01-2.03]), leucocyte count (OR: 1.46 [1.01-2.03]), leucocyte count ≥24 hr was the strongest predictor of AKI (≥5 units: OR: 3.68 p < 0.001; Figure) – the cutoff level used in the AKIN- and modified AKIN- criteria.

Potential triggers of blood transfusion such as baseline anemia, bleeding-vascular complications and peri-operative blood loss were not identified as predictors. Patients with severe baseline anemia had 2.4 times less blood loss but on average received 2.3 fold more units of blood transfusions in comparison to patients without anemia before TAVI (p < 0.001). AKI and life-threatening bleeding were independent predictors of 30-day mortality (OR: 3.04 [1.52-6.07], OR: 5.39 [2.14-13.57], respectively) while transfusion (≥3 units), baseline anemia and AKI predicted mortality beyond 30 days.

Conclusions: AKI occurred in 21% of the patients before TAVI. The number of blood transfusions but not the indication of transfusion predicted AKI. AKI was a predictor of both short- and long-term morality whereas blood transfusion predicted long-term mortality. These findings indicate that outcome of TAVI may be improved by more restrictive use of blood transfusions.

TCT-149 Impact of Chronic Kidney Disease on Myocardial Infarct Size and Adverse Events in ST-Elevation Myocardial Infarction: Results from the INFUSE-AMI Trial Usman Baker1, Roxana Mehran2, Sorin Brener3, Akiko Maehara4, Dariusz Duda5, Thomas Neutze6, D. Christopher Metzger7, C. Michael Gibson8, Gregg Stone9
1Mount Sinai School of Medicine, New York, NY, 2Mount Sinai School of Medicine, New York, NY, 3New York Methodist Hospital, Brooklyn, NY, 4Diabetes and Cardiovascular Research Foundation and Columbia University Medical Center, New York, NY, 5University Hospital, Krakow, Poland, 6AKH Vienna Austria, Vienna, Vienna, 7Wellmont CVA Heart Institute, Kingsport, USA, 8Beth Israel Deaconess Med Ctr - Harvard Medical School, Boston, USA, 9Columbia University Medical Center and the Cardiovascular Research Foundation, New York, NY

Background: Chronic kidney disease (CKD) patients have less favorable outcomes after ST-elevation myocardial infarction (STEMI) for yet unclear reasons. Methods: The INFUSE-AMI trial randomized patients with STEMI due to proximal or mid-LAD occlusion to intracoronary bolus abciximab (ClearWay RX catheter) vs. abciximab, and to thrombus aspiration (Export) vs. no aspiration. We compared infarct size as % of LV mass assessed by magnetic resonance imaging at 30-days, myocardial blush grade (MBG) 3 (64.4% vs. 70.5%, p = 0.35) was observed similarly in both groups. Median infarct size was non-significantly larger in CKD patients (19.3% vs. 17.0%, p = 0.34). The incidence of 30-day adverse events, were significantly higher in those with CKD (Figure). There were no significant differences in stent thrombosis, reinfarction or revascularization between groups.

Conclusions: Differences in infarct size between patients with and without CKD presenting with STEMI are modest and unlikely to account for the significantly higher short-term cardiac risk associated with CKD.

TCT-150 Prognostic Value of Different Definitions of Contrast Induced Acute Kidney Injury in STEMI: Analysis from the HORIZONS-AMI Trial Rudolf Jarai1, George Dangas2, Kurt Huber3, Roxana Mehran4, Gregg Stone5, Ke Xu6
1Wilhelminenhospital, Vienna, Austria, 2Department of Cardiology, Mount Sinai Medical Center, New York, New York City, NY, 3Dept Cardiology and Emergency Medicine, Wilhelminenhospital, Vienna, Austria, Vienna, Austria, 4Mount Sinai Hospital, New York, USA, 5Columbia University Medical Center and the Cardiovascular Research Foundation, New York, NY, 6Cardiovascular Research Foundation, New York, NY

Background: Several definitions of acute kidney injury (AKI) are in use, and the optimal absolute and relative increase of serum creatinine increase after contrast administration to define contrast-media induced acute kidney injury (CI-AKI) is still a matter of debate. Moreover, the prognostic relevance of AKI according to the varying definitions in STEMI has not been established.

Methods: Serum creatinine concentration data within 48h after coronary angiography was present in 2975 STEMI pts in the HORIZONS-AMI trial. Patients were analyzed according to different AKI definitions (AKIN-, modified AKIN- (mAKIN), Waikar-Bonventre (W-B), percent-changes of creatinine (<25%, 26-50%; 51-75%; >75%) and to the commonly used “standard-definition” of a relative increase in serum creatinine of ≥25% or an absolute increase of ≥0.5 mg/dl). The primary endpoint was all-cause mortality at 3 years.

Results: Depending on definitions the incidence of CI-AKI ranged from 5.0% to 15.5%. Similarly, 3-year mortality rates differed substantially with respect to the different CI-AKI definitions (Table). Absolute changes of creatinine were strongly associated with all-cause mortality, starting with an increase of 0.3mg/dl absolute increase of creatinine above baseline (HR 3.68 pc0.001). Figure – the cutoff level used in the AKIN- and modified AKIN-definitions. The increased risk associated with >0.3mg/dl absolute increase of creatinine was independent of the amount of contrast-media used.

Conclusions: The modified AKIN criteria might be the optimal definition for contrast-induced AKI after primary PCI in STEMI.